ROCKVILLE, Md.--(BUSINESS WIRE)--Precision Biologics is pleased to announce the completion of accrual to its Phase 2 study utilizing its novel monoclonal antibody Ensituximab (NPC-1C). NPC-1C targets a unique member of the MUC family that is specific to colorectal cancer with little reactivity to normal cells. Encouraging overall survival (OS) data was observed in the initial dose escalation phase in patients with chemotherapy refractory metastatic colorectal cancer. Patients in the preliminary study had an OS of 10.4 months, comparing favorably to the historical control for a similar population of patients (5.0 months). These results led to the current, statistically powered Phase 2 design of the study in 47 patients with colorectal cancer with a primary endpoint to increase overall survival after treatment with NPC-1C. Results of the Phase 2 study will be presented by Philip M. Arlen, MD, President and CEO of Precision Biologics at the Oxford Global 16th Annual Drug Summit and 3rd Annual Discovery Chemistry and Drug Designs Conference held on June 8th-9th, 2015 in Berlin, Germany. The presentation will be made available following the conference on the Precision Biologics website, www.Precision-Biologics.com. In addition, an abstract associated with this study is now available in the ASCO Proceedings for the 2015 Annual Meeting: J Clin Oncol 33, 2015 (suppl; abstr e14013) http://abstracts.asco.org/156/AbstView_156_148099.html
Founded in February 2012 and commencing business in late September 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. Precision Biologics is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials.